Pfizer sues over Accupril generic
Executive Summary
Newark, N.J. federal judge will hear arguments March 15 on Pfizer's request to preliminarily enjoin Teva and Ranbaxy from infringing an Accupril patent. Pfizer filed suit Jan. 28, alleging that the companies' generic quinapril infringes the patent. A court previously ruled that Teva's ANDA infringed, but Pfizer had not previously sued Ranbaxy. Teva began shipping quinapril manufactured under Ranbaxy's ANDA on Dec. 15 after Teva relinquished 180-day generic exclusivity rights (1"The Pink Sheet" Dec. 20, 2004, In Brief)...
|
Newark, N.J. federal judge will hear arguments March 15 on Pfizer's request to preliminarily enjoin Teva and Ranbaxy from infringing an Accupril patent. Pfizer filed suit Jan. 28, alleging that the companies' generic quinapril infringes the patent. A court previously ruled that Teva's ANDA infringed, but Pfizer had not previously sued Ranbaxy. Teva began shipping quinapril manufactured under Ranbaxy's ANDA on Dec. 15 after Teva relinquished 180-day generic exclusivity rights (1 'The Pink Sheet' Dec. 20, 2004, In Brief).... |